Leo CPA - Innovation Pharmaceuticals CEO, Chairman
| IPIX Stock | USD 0.0003 0.0001 25.00% |
Insider
Leo CPA is CEO, Chairman of Innovation Pharmaceuticals
| Age | 65 |
| Phone | 978 921 4125 |
| Web | https://www.ipharminc.com |
Innovation Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3177) % which means that it has lost $0.3177 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0946) %, meaning that it created substantial loss on money invested by shareholders. Innovation Pharmaceuticals' management efficiency ratios could be used to measure how well Innovation Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | INSIDER Age | ||
| Robert Madden | Grey Cloak Tech | 51 | |
| Scott Landers | Grey Cloak Tech | N/A | |
| Kevin Pitts | Grey Cloak Tech | 63 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.32 |
Innovation Pharmaceuticals Leadership Team
Elected by the shareholders, the Innovation Pharmaceuticals' board of directors comprises two types of representatives: Innovation Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovation. The board's role is to monitor Innovation Pharmaceuticals' management team and ensure that shareholders' interests are well served. Innovation Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovation Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leo CPA, CEO, Chairman | ||
| MS MP, VP Management | ||
| Jim Boeheim, B Advisor | ||
| James Alexander, Consultant |
Innovation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Innovation Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (339.83) % | |||
| Current Valuation | 7.56 M | |||
| Shares Outstanding | 488.32 M | |||
| Shares Owned By Insiders | 10.10 % | |||
| Price To Earning | (7.57) X | |||
| Price To Book | 2.95 X | |||
| Price To Sales | 557.16 X | |||
| Revenue | 18 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.